Original Articles
28 June 2024
Vol. 2 No. 2 (2024)
Treatment pathways in patients with heart failure with preserved ejection fraction and obesity: perspectives from cardiology specialists and patients
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
1772
Views
1002
Downloads
3
HTML
Authors
Background: Obesity, highly prevalent in patients with heart failure with preserved ejection fraction (HFpEF), may make HFpEF more difficult to diagnose by masking its signs. The aim of this study was to identify challenges patients and healthcare professionals (HCPs) face in diagnosing and treating patients with HFpEF and obesity.
Methods: An anonymous, US populationbased online survey was conducted in September 2020 among 114 patients with obesity and a selfreported diagnosis of HFpEF and 200 HCPs.
Results: In the typical medical journey, almost half of patients (45%) were diagnosed with HFpEF within one month of discussing symptoms with an HCP; however, the remaining patients waited an average of 22 months for diagnosis, most of whom (78%) received their diagnosis from a cardiologist. Most patients (65%) perceived their cardiologist as the coordinator of their HFpEF care. The treatments most recommended by cardiologists for the ongoing treatment of HFpEF included lifestyle changes (91%), diuretics (87%), beta blockers (76%), and angiotensinconverting enzyme inhibitors (71%). Heart failure specialists (29%) were more likely than general cardiology specialists (12%) to report recommending prescription weightloss medications for management of HFpEF. Most cardiologists reported not having received formal training in obesity management.
Conclusions: Cardiology specialists play a central role in the diagnosis and management of HFpEF, but optimal coordination is needed to improve obesity management in patients with HFpEF.
Altmetrics
Downloads
Download data is not yet available.
Citations
Afshin A, Forouzanfar MH, Reitsma MB, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017;377:13-27. DOI: https://doi.org/10.1056/NEJMoa1614362
Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 2008;32:1431-7. DOI: https://doi.org/10.1038/ijo.2008.102
Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305-13. DOI: https://doi.org/10.1056/NEJMoa020245
Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2017;14:591-602. DOI: https://doi.org/10.1038/nrcardio.2017.65
Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol 2020;76:2982-3021. DOI: https://doi.org/10.1016/j.jacc.2020.11.010
Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 2017;136:6-19. DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.026807
Kitzman DW, Lam CSP. Obese heart failure with preserved ejection fraction phenotype. Circulation 2017;136:20-3. DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.028365
Reddy YNV, Lewis GD, Shah SJ, et al. Characterization of the obese phenotype of heart failure with preserved ejection fraction: a RELAX trial ancillary study. Mayo Clin Proc 2019;94:1199-209. DOI: https://doi.org/10.1016/j.mayocp.2018.11.037
Obokata M, Reddy YNV, Melenovsky V, Sorimachi H, Jarolim P, Borlaug BA. Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity. Eur J Heart Fail 2022;24:353-61. DOI: https://doi.org/10.1002/ejhf.2377
Reddy YNV, Rikhi A, Obokata M, et al. Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity. Eur J Heart Fail 2020;22:1009-18. DOI: https://doi.org/10.1002/ejhf.1788
Adamson C, Kondo T, Jhund PS, et al. Dapagliflozin for heart failure according to body mass index: the DELIVER trial. Eur Heart J 2022;43:4406-17. DOI: https://doi.org/10.1093/eurheartj/ehac481
Kitzman DW, Brubaker P, Morgan T, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical Trial. JAMA 2016;315:36-46. DOI: https://doi.org/10.1001/jama.2015.17346
Sorimachi H, Obokata M, Omote K, et al. Long-term changes in cardiac structure and function following bariatric surgery. J Am Coll Cardiol 2022;80:1501-12. DOI: https://doi.org/10.1016/j.jacc.2022.08.738
Reddy YNV, Anantha-Narayanan M, Obokata M, et al. Hemodynamic effects of weight loss in obesity: a systematic review and meta-analysis. JACC Heart Fail 2019;7:678-87. DOI: https://doi.org/10.1016/j.jchf.2019.04.019
Verbrugge FH, Omote K, Reddy YNV, Sorimachi H, Obokata M, Borlaug BA. Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality. Eur Heart J 2022;43:1941-51. DOI: https://doi.org/10.1093/eurheartj/ehab911
van Veldhuisen DJMDP, Linssen GCMMDP, Jaarsma TRNP, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013;61:1498-506. DOI: https://doi.org/10.1016/j.jacc.2012.12.044
Mueller C, McDonald K, de Boer RA, et al. Heart failure association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019;21:715-31. DOI: https://doi.org/10.1002/ejhf.1494
Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594-600. DOI: https://doi.org/10.1161/01.CIR.0000112582.16683.EA
Khan SS, Huffman MD, Shah SJ. Could a low-dose diuretic polypill improve outcomes in heart failure with preserved ejection fraction? Circulation 2021;14:e008090. DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.120.008090
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. New Engl J Med 2021;385:1451-61. DOI: https://doi.org/10.1056/NEJMoa2107038
Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089-98. DOI: https://doi.org/10.1056/NEJMoa2206286
Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. New Engl J Med 2020;384:117-28. DOI: https://doi.org/10.1056/NEJMoa2030183
Gallgher A. FDA approves expanded label for dapagliflozin to reduce risk of cardiovascular death, hospitalization from heart failure. Pharmacy Times, May 9, 2023. Available from: https://www.pharmacytimes.com/view/fda-approves-expanded-label-for-dapagliflozin-to-reduce-risk-of-cardiovascular-death-hospitalization-from-heart-failure (accessed June 14, 2023).
Sorimachi H, Obokata M, Takahashi N, et al. Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction. Eur Heart J 2021;42:1595-605. DOI: https://doi.org/10.1093/eurheartj/ehaa823
Sorimachi H, Burkhoff D, Verbrugge FH, et al. Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction. Eur J Heart Fail 2021;23:1648-58. DOI: https://doi.org/10.1002/ejhf.2254
Sorimachi H, Omote K, Omar M, et al. Sex and central obesity in heart failure with preserved ejection fraction. Eur J Heart Fail 2022;24:1359-70. DOI: https://doi.org/10.1002/ejhf.2563
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Card Fail 2022;28:e1-167 DOI: https://doi.org/10.1016/j.cardfail.2022.02.009
Bramante CT, Raatz S, Bomberg EM, Oberle MM, Ryder JR. Cardiovascular risks and benefits of medications used for weight loss. Front Endocrinol 2019;10:883. DOI: https://doi.org/10.3389/fendo.2019.00883
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Design and baseline characteristics of STEP-HFpEF program evaluating semaglutide in patients with obesity HFpEF phenotype. JACC Heart Fail 2023;11:1000-10. DOI: https://doi.org/10.1016/j.jchf.2023.05.010
How to Cite
1.
Butler J, Shah SJ, Magwire M, Campos C, Usman MS, Hoovler A, et al. Treatment pathways in patients with heart failure with preserved ejection fraction and obesity: perspectives from cardiology specialists and patients. Global Cardiol [Internet]. 2024 Jun. 28 [cited 2025 Aug. 17];2(2). Available from: https://www.globalcardiology.info/site/article/view/38
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Jelena Čelutkienė, Agnė Monika Jakštaitė, Jolita Badarienė, Svetlana Solovjova, Ieva Slivovskaja, Rokas Navickas, Edita Kazėnaitė, Egidija Rinkūnienė, Alma Čypienė, Jonas Misiūra, Ligita Ryliškytė, Aleksandras Laucevičius, Andrew J.S. Coats, Detection of early heart failure with preserved ejection fraction in metabolic syndrome patients detected as part of a national screening program in middle aged subjects , Global Cardiology: Vol. 1 No. 1 (2023)
- Sven Christopher Aland, Christoph Gertler, Hannah Leonie Bräunig, Timo Schröder, Frank Edelmann, Rolf Wachter, Christoph Herrmann-Lingen, Gerd Hasenfuß, Anja Sandek, Exercise capacity, iron deficiency and depressive symptoms in patients with asymptomatic chronic systolic heart failure , Global Cardiology: Vol. 2 No. 2 (2024)
- Elena Efremova, Alexander Shutov, Adherence to lifestyle therapy in patients with chronic heart failure and comorbidity , Global Cardiology: Vol. 1 No. 1 (2023)
- Khawaja M. Talha, Javed Butler, Stephan von Haehling, Mitja Lainscak, Piotr Ponikowski, Stefan D. Anker, Defining iron replete status in patients with heart failure treated with intravenous iron , Global Cardiology: Vol. 1 No. 1 (2023)
- Maryanne Caruana, Miriam Gatt, Oscar Aquilina, Charles Savona Ventura, Victor Grech, Jane Somerville, The impact of maternal congenital heart disease on pregnancy outcomes in Malta: a retrospective study , Global Cardiology: Vol. 1 No. 1 (2023)
- Muhammad Shahzeb Khan, Javed Butler, Laibah Arshad Khan, Markus S. Anker, Advanced cancer as a heart failure like syndrome due to cardiac wasting cardiomyopathy: facts and numbers , Global Cardiology: Vol. 2 No. 4 (2024)
- Stefan D. Anker, Javed Butler, Khawaja M. Talha, Tim Friede, Using multiple primary endpoints in clinical trials with a focus on heart failure , Global Cardiology: Vol. 2 No. 2 (2024)
- Maryanne Caruana, Philip Moons, Adrienne H. Kovacs, Koen Luyckx, Corina Thomet, Werner Budts, Maayke Sluman, Katrine Eriksen, Mikael Dellborg, Malin Berghammer, Bengt Johansson, Alexandra Soufi, Edward Callus, Victor Grech, Silke Apers, Quality of life in Maltese adults with congenital heart disease: a second look , Global Cardiology: Vol. 2 No. 1 (2024)
- Vijay Chopra, Muhammad Shahzeb Khan, Magdy Abdelhamid, William T. Abraham, Offer Amir, Stefan D. Anker, John J. Atherton, Fernando Bacal, Ralph Stephan von Bardeleben, Dulce Brito, Lucrecia Maria Burgos, Javed Butler, Maria Rosa Costanzo, Albertino Damasceno, Justin A. Ezekowitz, Ishaque Hameed, Sivadasanpillai Harikrishnan, Tiny Jaarsma, Anuradha Lala, Ileana L. Piña, Clara Saldarriaga, David Sim, John R. Teerlink, Nqoba Tsabedze, Hiroyuki Tsutsui, Jing Yu, Yuhui Zhang, Mohammad Zubaid, Nikhil Balankhe, Juan Esteban Gomez-Mesa, James L. Januzzi, Marvin Konstam, Rhonda Monroe, Elijah Ogola, Vinayagam Palaniappan, Mark C. Petrie, Fausto J. Pinto, Girish C. Rajadhyaksha, Amina Rakisheva, Carlos E. Ramos, Victor Rossel, Naoki Sato, P. Christian Schulze, Andrew Sindone, Hadi N. Skouri, Harriette G.C. Van Spall, Aistė Štaraitė, Lynne Warner Stevenson, Kadhim Sulaiman, Tzung-Dau Wang, Michael Böhm, Andrew J.S. Coats, Shelley Zieroth, iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025 , Global Cardiology: Vol. 3 No. 2 (2025)
- Enrico Cerrato, Ilaria Meynet, Giorgio Quadri, Federico Giacobbe, Cristina Rolfo, Francesco Tomassini, Fabio Ferrari, Fabio Mariani, Luca Lo Savio, Matteo Bianco, Paola Destefanis, Alessia Luciano, Carol Gravinese, Emanuele Tizzani, Sara Giolitto, Antonella Corleto, Fabrizio D’Ascenzo, Umberto Barbero, Fernando Macaya, Javier Escaned, Roberto Pozzi, Ferdinando Varbella, Acute interventional management of spontaneous coronary artery dissection: case series and literature review , Global Cardiology: Vol. 2 No. 1 (2024)
You may also start an advanced similarity search for this article.
